
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc has demonstrated a strong performance, reporting a revenue of $98.6 million for the second quarter of 2025, marking a year-over-year growth of approximately 13%, with notable contributions from its wound care and surgical segments. The company is optimistic about future growth, increasing its revenue estimate for 2025 to $387.3 million, which reflects confidence in its expanding surgical business. Despite an increase of about 16% year-over-year in selling, general, and administrative expenses, driven by higher sales commissions and legal costs, the underlying growth in key product categories supports a positive financial trajectory.
Bears say
MiMedx Group Inc reported a decline in gross margin, decreasing to approximately 81% from 83% in the second quarter of 2025, attributed to production variances and product mix issues. Although the company maintains its guidance for low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, the potential for adverse changes in reimbursement rates from CMS raises significant concerns regarding future revenue stability. This combination of declining margins and the uncertainty surrounding reimbursement policies contributes to a negative outlook for MiMedx Group's stock.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares